Table 2 The location of additional malignancies in 644 μm patients from the studied cohort

C00

Lip

2

2%

1

2%

1

1%

C16

Stomach

5

4%

1

2%

4

6%

C18

Colon

10

8%

5

9%

5

7%

C20

Rectum

3

2%

1

2%

2

3%

C25

Pancreas

1

1%

0

0%

1

1%

C32

Larynx

3

2%

1

2%

2

3%

C34

Bronchus and lung

15

12%

5

9%

10

14%

C43

Malignant melanoma of skin

3

2%

2

4%

1

1%

C44

Other skin malignancies

17

13%

6

11%

11

15%

C45

Mesothelioma

1

1%

1

2%

0

0%

C49

Malignant neoplasm of other

connective and soft tissue

1

1%

1

2%

0

0%

C50

Breast

17

13%

16

29%

1

1%

C51

Vulva

1

1%

1

2%

0

0%

C53

Cervix uteri

1

1%

1

2%

0

0%

C54

Corpus uteri

6

5%

6

11%

0

0%

C56

Ovary

3

2%

3

5%

0

0%

C61

Prostate

14

11%

0

0%

14

20%

C64

Kidney

3

2%

0

0%

3

4%

C67

Bladder

10

8%

0

0%

10

14%

C73

Thyroid gland

2

2%

2

4%

0

0%

C83

Non-follicular lymphoma

1

1%

1

2%

0

0%

C85

Other specified and unspeified types of non-Hodgkin lymphoma

1

1%

0

0%

1

1%

C91

Lymphoid leukemia

1

1%

0

0%

1

1%

C92

Myeloid leukemia

2

2%

0

0%

2

3%

D03

Melanoma in situ

1

1%

0

0%

1

1%

D09

Carcinoma in situ of bladder

1

1%

1

2%

1

1%

D45

Polycythemia vera

1

1%

0

0%

1

1%

126

55

71